Wealth Advisory Solutions LLC Reduces Holdings in Eli Lilly and Company (NYSE:LLY)

Wealth Advisory Solutions LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,892 shares of the company’s stock after selling 494 shares during the period. Eli Lilly and Company comprises 3.9% of Wealth Advisory Solutions LLC’s holdings, making the stock its 6th largest position. Wealth Advisory Solutions LLC’s holdings in Eli Lilly and Company were worth $14,079,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Prio Wealth Limited Partnership increased its stake in shares of Eli Lilly and Company by 0.5% during the 3rd quarter. Prio Wealth Limited Partnership now owns 2,411 shares of the company’s stock worth $2,136,000 after purchasing an additional 11 shares during the last quarter. Trilogy Capital Inc. grew its holdings in Eli Lilly and Company by 3.9% during the third quarter. Trilogy Capital Inc. now owns 1,347 shares of the company’s stock valued at $1,193,000 after purchasing an additional 51 shares during the period. Penn Davis Mcfarland Inc. purchased a new stake in Eli Lilly and Company in the third quarter worth $2,007,000. Calton & Associates Inc. raised its stake in shares of Eli Lilly and Company by 1,735.7% in the third quarter. Calton & Associates Inc. now owns 19,000 shares of the company’s stock valued at $16,833,000 after buying an additional 17,965 shares during the period. Finally, ACT Advisors LLC. lifted its position in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. ACT Advisors LLC. now owns 278 shares of the company’s stock valued at $246,000 after buying an additional 14 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock traded down $9.89 during trading on Monday, hitting $908.08. The company had a trading volume of 424,724 shares, compared to its average volume of 2,971,750. The stock’s 50-day moving average is $921.21 and its two-hundred day moving average is $858.60. The stock has a market capitalization of $863.04 billion, a price-to-earnings ratio of 134.33, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on LLY shares. Sanford C. Bernstein started coverage on Eli Lilly and Company in a report on Thursday. They issued an “outperform” rating and a $1,100.00 price objective for the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Barclays lifted their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.